Document Detail

Durability of antidepressant response to vagus nerve stimulation (VNS).
MedLine Citation:
PMID:  17288644     Owner:  NLM     Status:  MEDLINE    
This study characterized the durability of improvement in patients who responded early or late while receiving vagus nerve stimulation (VNS). In both a pilot and pivotal study, patients were identified who had at least a 50% reduction in symptom scores 3 months (early responders) or 12 months (late responders) after starting VNS. Probabilities were determined for maintenance of response at 12-month and 24-month time-points. Consistency of improvement throughout the 24-month study period was evaluated, testing for change in serial depression ratings. In the pilot study, 30.5%, 23.7% and 45.8% were early responders, later responders, and non-responders, respectively. These rates were 14.6%, 19.5%, and 65.9% in the pivotal trial. The potential confound of alterations in antidepressant treatment was examined in the pivotal trial. In the pilot study, 72.2% and 61.1% of early responders (n=18) were responders at 12 and 24 months, respectively; 78.8% of late responders (n=14) were responders at 24 months. In the pivotal trial, of early responders (n=30), 63.3% and 76.7% maintained response at 12 and 24 months, respectively; of late responders (n=40), 65.0% maintained response at 24 months. Early and late responders had fewer changes in medication than non-responders across the pivotal study period. In both studies, analyses of serial depression ratings showed stable improvement in early and late responders. These samples had exceptional levels of chronicity and treatment resistance. Yet patients who showed substantial clinical benefit maintained the improvement at remarkably high rates. This durability of benefit was not attributable to alterations in other treatments.
Harold A Sackeim; Stephen K Brannan; A John Rush; Mark S George; Lauren B Marangell; John Allen
Related Documents :
16475994 - A prospective assessment of an 'a la carte' regimen of peg-interferon alpha2b and ribav...
7840914 - Treatment options in zidovudine intolerance or failure.
12076394 - Interferon for interferon naive patients with chronic hepatitis c.
25021814 - Pth-119 high definition (hd) endoscopy with i-scan for the detection of markers of co...
8627834 - Outcome analysis of goal directed therapy for impotence.
18726154 - Synbiotics decrease the incidence of septic complications in patients with severe sirs:...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-02-09
Journal Detail:
Title:  The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)     Volume:  10     ISSN:  1461-1457     ISO Abbreviation:  Int. J. Neuropsychopharmacol.     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-10-31     Completed Date:  2008-01-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9815893     Medline TA:  Int J Neuropsychopharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  817-26     Citation Subset:  IM    
Departments of Biological Psychiatry , New York State Psychiatric Institute, New York, NY 10032, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Antidepressive Agents / administration & dosage,  therapeutic use
Bipolar Disorder / psychology,  therapy
Depression / drug therapy,  psychology,  therapy*
Electric Stimulation Therapy*
Middle Aged
Pilot Projects
Psychiatric Status Rating Scales
Randomized Controlled Trials as Topic
Time Factors
Vagus Nerve / physiology*
Reg. No./Substance:
0/Antidepressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The impact of contact structure on infectious disease control: influenza and antiviral agents.
Next Document:  Mitochondrial DNA-dependent effects of valproate on mitochondrial calcium levels in transmitochondri...